`
`
`
`
`
`
`
`
`
`
`
`
`
` Curriculum Vitae
`
`JOHN PETER BANTLE, M.D.
` December 2022
`
`Office Address: MMC 101
`
`University of Minnesota
`Minneapolis, MN 55455
`
`
`
`
`
`
`
`
`
`
`Universities Attended:
`1965 - 1968 University of Minnesota, Minneapolis, Minnesota
`1968 - 1972 University of Minnesota Medical School, Minneapolis, Minnesota
`
`Degrees:
`
`
`1970 Bachelor of Science
`1972 Doctor of Medicine
`
`Professional Training:
`
`Internship
`
` Rotating Internship with medicine emphasis
`
` Cleveland Metropolitan General Hospital
`
` Cleveland, Ohio
`
`
`July 1972 - June 1973
`
`Residency
`
`
`Internal Medicine
`
` Mayo Clinic
`
` Rochester, Minnesota
`
`
`July 1973 - September 1975
`
`Fellowship
`
`
`Endocrinology and Metabolism
`
` University of Minnesota
`
` Minneapolis, Minnesota
`
`
`July 1976 - June 1978
`
`State License: Minnesota (No. 21141)
`
`Board Certification:
`1975 American Board of Internal Medicine (certification number 50035)
`1979 Endocrinology and Metabolism (certification number 50035)
`
`Professional Experience:
`
`
`Instructor, Department of Medicine
`
`University of Minnesota Medical School
`
`July 1978 - June 1979
`
`
`Assistant Professor, Department of Medicine
`
`University of Minnesota Medical School
` July 1979 - June 1987
`
`
`
` Associate Professor, Department of Medicine
`
`University of Minnesota Medical School
`
`July 1987 - June 1996
`
`
`
`Internal Medicine (Registrar)
`Dunedin Public Hospital
`Dunedin, New Zealand
`November 1975 - February 1976
`
`MPI EXHIBIT 1027 PAGE 1
`
`

`

`
`Professor, Department of Medicine
`
`University of Minnesota Medical School
`
`July 1996 - December 2016
`
`
`Professor Emeritus
`
`University of Minnesota Medical School
`
`January 2017 - present
`
`
`Associate Director, General Clinical Research Center
`
`University of Minnesota Medical School
`
`July 1983 - November 2009
`
`
`Medical Staff Clinical Service Chief for Internal Medicine
`
`Fairview-University Medical Center
`
`January 2001 - May 2007
`
`
` Interim Director, Division of Endocrinology and Diabetes
` Department of Medicine
` University of Minnesota Medical School
` October 2008 - April 2010
`
` Director, Division of Endocrinology and Diabetes
` Department of Medicine
` University of Minnesota Medical School
` May 2010 – March 2015
`
` Leader, Clinical Research Implementation Services (CRIS)
` Clinical and Translational Science Institute (CTSI)
` University of Minnesota
` August 2011 - 2013
`
`Membership in Organizations:
`
`American Diabetes Association
`
`The Endocrine Society
`
`Honors and Awards:
`
`Alpha Omega Alpha, University of Minnesota Medical School, 1972
`
`Nominated for Minnesota Medical Foundation Distinguished Clinical Teacher Award in
`1992 and 1993
` Recipient of Department of Medicine 2002 Clinical Excellence Award
` Recipient of Department of Medicine 2004 Clinical Excellence Award
` Recipient of Department of Medicine 2011 Clinical Excellence Award
` Named in the Minneapolis/St. Paul Magazine surveys of Twin Cities doctors and nurses
`as a leading doctor in his specialty; i.e., one they would pick for their own care, in
`1992, 1994, 1996, 1999, 2000, 2001, 2002, 2004, 2006, 2007, 2008, 2009, 2010, 2011,
`2012, 2013, 2014, 2015, 2016 and 2017.
`Selected by peers to be included in Best Doctors in America 1996, 1997, 1998, 1999, 2000,
`2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014,
`2015, 2016 and 2017.
`
`
`
`
`Service at the National Level
`Member of the American Diabetes Association Committee which developed 1994 diabetes
`nutrition recommendations
`
`
`
`2
`
`MPI EXHIBIT 1027 PAGE 2
`
`

`

`
`Member of the American Diabetes Association Committee which developed the 1998 standards
`of care for people with diabetes
`Co-Chair of the American Diabetes Association Committee which developed 2002 diabetes
`nutrition recommendations
`Co-Chair of the American Diabetes Association Committee which developed 2006 diabetes
`nutrition recommendations
`
`
`
`Service to the University
`Elected member University of Minnesota Physicians Board of Directors (2006 - 2009)
`Elected member University of Minnesota Senate (1999 - 2002, 2007 - 2010)
`
`Service to the Department of Medicine
`Medical Staff Clinical Service Chief (2001 - 2007)
`Elected member Department of Medicine Board of Governors (two terms, 1999 - 2005)
`Member Promotion and Tenure Committee (1997 - 2003)
`Medical Director, Diabetes Education and Self-Management Program (1995 - 2000)
`
`Selected Regional, National and International Lectures and Symposia:
`Postprandial Responses to Meals Containing Sugars and Starches. NIH Seminar of Nutrition
`Coordinating Committee, Bethesda, MD, September 8, 1983.
`Metabolic Effects of Dietary Fructose. American Medical Association Resource Conference on
`Fructose, Chicago, IL, October 1-2, 1984.
`Effects of Dietary Sucrose and Fructose. NIH Diabetes Update, Bethesda, MD, March 30, 1985.
`The Glycemic Effects of Dietary Carbohydrates. NIH Consensus Development Conference on
`Diet and Exercise in NIDDM, Bethesda, MD, December 8-10, 1986.
`Dietary Fructose and Sucrose in People with Diabetes. UCSF and Northern California American
`Diabetes Association Affiliate Symposium on Sweeteners in Diabetes, San Francisco, CA,
`March 20, 1987.
`Dietary Carbohydrates and their Effect on Plasma Glucose. American Diabetes Association
`Symposium on Nutrition and Metabolism, San Francisco, CA, October 6-8, 1988.
`Current Controversy: Carbohydrate and Fat. American Diabetes Association Council on
`Nutritional Sciences and Metabolism, Las Vegas, NV, June 12, 1993.
`Diabetes Control and Complications Update. American Dietetic Association National Meeting,
`Anaheim, CA, October 28, 1993.
`Nutritional Issues in the Management of NIDDM. American Diabetes Association Annual
`Advanced Postgraduate Course, Boston, MA, January 28-30, 1994.
`Controversies in the Nutritional Management of Diabetes. University of Iowa, Iowa City, IA,
`April 27, 1995.
`Current Trends in Obesity Management for Diabetes. American Diabetes Association Utah
`Affiliate, Salt Lake City, UT, May 12, 1997.
`Health Implications of Obesity: A Focus on Diabetes. American Diabetes Association Annual
`Meeting, Boston, MA, June 21, 1997.
`Current Nutrition Recommendations of the American Diabetes Association. American College
`of Nutrition Annual Meeting, New York, NY, September 27, 1997.
`Obesity and Type 2 Diabetes. Video Conference sponsored by the University of Minnesota and
`the American Diabetes Association, New York, NY, February 25, 1998.
`Intensive Treatment of Type 1 Diabetes Mellitus. St. Louis University, St. Louis, MO, October
`5, 2001.
`Evidence Based Nutrition Recommendations for Diabetes: 2001. American Dietetic Association
`National Meeting, St. Louis, MO, October 21, 2001.
`Glycemic Index: Scientific Merit and Clinical Utility. American Diabetes Association Annual
`Meeting, San Francisco, CA, June 15, 2002.
`
`
`
`3
`
`MPI EXHIBIT 1027 PAGE 3
`
`

`

`
`
`
`A Combination of Food Based Strategies and Pharmacotherapy for Weight Reduction in Type 2
`Diabetes. European Congress on Obesity, Helsinki, Finland, May 30, 2003.
`Prevention and Treatment of Diabetes Mellitus. St. Louis University, St. Louis, MO, November
`7,2003.
`Weight Loss as Primary Therapy for Type 2 Diabetes Mellitus. National (Mexican) Congress on
`Diabetes, Acapulco, Mexico, March 10, 2005.
`Is Fructose the Optimal Low Glycemic Index Sweetener? Nestle Symposium on Nutritional
`
`Management of Diabetes Mellitus and Dysmetabolic Syndrome, Hangzhou, China, October
`30 – November 2, 2005 (meeting Co-Chairman).
`Do Fructose and Sugar Alcohols make a Difference in Diabetes and Weight Control? American
`Diabetes Association Annual Advanced Postgraduate Course, San Francisco, CA, February
`11, 2006.
`Nutrition Guidelines for Diabetes – A Focus on Carbohydrates. Satellite Symposium,
`International Diabetes Federation World Congress, Cape Town, South Africa, December 6,
`2006.
`Keynote: Management of Type 2 Diabetes. University of Nebraska conference Management of
`Diabetes and Complications, Omaha, NE, March 30, 2007.
`Factors to Consider when Conducting Research on Fructose and Metabolic Syndrome and
`Diabetes. ILSI North America and United States Department of Agriculture Symposium on
`The State of the Science on Dietary Sweeteners Containing Fructose, Beltsville, MD,
`March 19-19, 2008.
`Non-Pharmacologic Therapy of Type 2 Diabetes. Meet-the-Professor Session. Endocrine Society
`Annual Meeting, San Francisco, CA, June 16, 2008.
`The Diabetes Epidemic. CME Institute, Maui, HI, March 1, 2010.
`Bariatric Surgery and Type 2 Diabetes: For Whom, How and At What Point in the Natural
`History? American Diabetes Association 58th Annual Advanced Postgraduate Course, New
`York, NY, February 27, 2011.
`Clinical Research Strategies for Fructose Metabolism, NIH, Bethesda, MD, November 13-14,
`2012 (Session I Chair).
`Metabolic Surgery: Advantages and Disadvantages. American Diabetes Association 60th Annual
`Advanced Postgraduate Course, New York, NY, February 24, 2013.
`Bariatric Surgery as Treatment for Type 2 Diabetes Mellitus: An Endocrinologist’s Perspective.
` Fifth Asian Diabetes Surgery Summit, Taipei, Taiwan, October 25, 2014.
`Post-Bariatric Surgery Hypoglycemia. Meet-the-Professor Session. Endocrine Society Annual
`Meeting, Boston, MA, April 2, 2016.
`Post-Bariatric Surgery Hyperinsulinemic Hypoglycemia. University of Indiana, Indianapolis, IN,
`February 8, 2017.
`Medical Approach to Obesity Management. Seventh Emirates Diabetes and Endocrine Congress.
`Dubai, United Arab Emirates, February 17, 2017.
`
`
`
`Areas of Research Interest:
`
`1.
`Intensive treatment of diabetes mellitus
`
`2. Dietary treatment of diabetes mellitus
`
`3. Metabolic effects of dietary carbohydrates
`
`4. Treatment of obesity
`
`Chronology of Grants and Research Support as Principal Investigator or Co-Principal
`Investigator:
`
`
`4
`
`MPI EXHIBIT 1027 PAGE 4
`
`

`

`
`
`Archer, Daniels, Midland Foundation (1981-1983) $12,000
`"Plasma Glucose Response to Various Forms of Dietary Carbohydrate"
`
`Sandoz, Inc. (1983-1984) $7,000
`"Potassium Clearance in Renal Transplant Recipients Receiving Cyclosporine"
`
`American Diabetes Association, Inc. (1983-1985) $49,568
`"Comparison of Fructose, Sucrose and Starch in the Diabetic Diet"
`
`The Estee Corporation (1983-1985) $14,000
`"Comparison of Fructose, Sucrose and Starch in the Diabetic Diet"
`
`Sandoz, Inc. (1984-1986) $17,920
`"Effects of Cyclosporine on the Renin-Angiotensin-Aldosterone System"
`
`American Diabetes Association, Minnesota Affiliate (1985-1986) $5,000
`"Comparison of the Diabetic Exchange Lists and the Glycemic Index of Foods"
`
`Public Health Service, NIH NIDDK (1985-1996) $2,732,116
`“Diabetes Control and Complications Trial (DCCT)”
`
`Sandoz, Inc. (1987-1988) $15,000
`"Trial of Alpha Adrenergic Blockade to Prevent Cyclosporine Nephrotoxicity"
`
`The International Fructose Association (1987-1991) $100,000
`"Metabolic Effects of Chronic Dietary Fructose and Sucrose Consumption"
`
`Eli Lilly and Company (1989) $4,700
`"Effects of Rotating Insulin Injection Sites in Type I Diabetic Subjects"
`
`Roerig Division, Pfizer Incorporated (1990-1992) $100,385
`"Effects of Two Different Dietary Regimens on Glucose and Lipid Metabolism in Glipizide
`Treated Patients with NIDDM"
`
`Integ, Inc. (1996-1997) $35,933
`“The Use of Dermal Interstitial Fluid for Glucose Monitoring”
`
`American Diabetes Association (1997-1998) $72,406
`“Pharmacologic Induction of Weight Loss to Treat Type 2 Diabetes Mellitus”
`
`Smith Kline Beecham Pharmaceuticals (1998) $10,000
`“Plasma Serotonin in Fenfluramine and Phentermine Treated Patients”
`
`Medtronic, Inc. (1999-2000) $29,834
`"ECG Analysis for Blood Glucose Monitoring"
`
`Abbott Laboratories and Slim Fast Foods Company (2000-2003) $333,297
`"Combination Weight Loss Therapy for Type 2 Diabetes Mellitus"
`
`Public Health Service, NIH NHLBI (2001-2010) $1,115,950
`"Bypass Angioplasty Revascularization 2 Diabetes (BARI 2D)"
`
`Public Health Service, NIH NIDDK (2002-2022) $1,393,783 for most recent 5 years
`"Action for Health in Diabetes Extension Study (Look AHEAD)"
`
`5
`
`MPI EXHIBIT 1027 PAGE 5
`
`

`

`
`Role: Co-Principal Investigator,
`
`Current Grant Support:
`
`Public Health Service, NIH NIDDK (7/1/2017-6/30/2022) $157,894 for current year
`“Epidemiology of Diabetes Intervention and Complications (EDIC)”
`Role: Principal Investigator, 6% effort
`
`
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`6.
`7.
`
`8.
`
`9.
`
`Publications in Peer Reviewed Journals
`
`Bantle JP, Dillmann WH, Oppenheimer JH, Bingham C, Runger GC. Common clinical
`indices of thyroid hormone action: relationships to serum free T3 concentration and
`estimated nuclear occupancy. J Clin Endocrinol Metab 1980;50:286-293.
`Bantle JP, Oppenheimer JH, Schwartz HL, Hunninghake DB, Probstfield JL, Hanson RF.
`TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded
`doses of dextrothyroxine. Metabolism 1981;30:63-66.
`Schuster LD, Bantle JP, Oppenheimer JH, Seljeskog EL. Acromegaly: reassessment of
`the long-term therapeutic effectiveness of transphenoidal pituitary surgery. Ann Intern
`Med. 1981;95:172-174.
`Bantle JP, Seelig S, Mariash CN, Ulstrom RA, Oppenheimer JH. Resistance to thyroid
`hormones: a disorder frequently confused with Graves' disease. Arch Intern Med 1982;
`142:1867-1871. Summarized in 1984 Year Book of Medicine.
`Mitchell JE, Bantle JP. Metabolic and endocrine investigations in women of normal
`weight with the bulimia syndrome. Biol Psychiatry 1983;18:355-365.
`Bantle JP, Beyer S, Oppenheimer JH. Recurrent episodes of spontaneously resolving
`hyperthyroidism due to thyroiditis. Minn Med 1983;66:295-297.
`Bantle JP, Laine DC, Castle GW, Thomas JW, Hoogwerf BJ, Goetz FC. Postprandial
`glucose and insulin responses to meals containing sugars or starches in normal and
`diabetic subjects. N Engl J Med 1983;309:7-12. Summarized in 1984 Year Book of
`Medicine.
`Hoogwerf BJ, Barbosa JJ, Bantle JP, Laine DC, Goetz FC. Urinary C-peptide as a
`measure of beta cell function following a mixed meal in healthy subjects: comparison of
`four hour urine C-peptide with serum insulin and plasma C-peptide. Diabetes Care 1983;
`6:488-492.
`Bantle JP, Laine DC, Hoogwerf BJ, Goetz FC. The potential usefulness of postprandial
`urine C-peptide measurement in classifying diabetic patients. Diabetes Care 1984;7:202-
`203 (letter).
`Hoogwerf BJ, Bantle JP, Kuba K, Frantz ID, Hunninghake DB. Treatment of type III
`hyperlipoproteinemia with four different treatment regimens. Atherosclerosis 1984;51:
`251-259.
`11. Mascioli SR, Bantle JP, Freier EF, Hoogwerf BJ. Artifactual elevation of serum
`creatinine due to fasting. Arch Intern Med 1984;144:1575-1576. Summarized in 1985
`Year Book of Medicine.
`Bantle JP, Hunninghake DB, Frantz ID, Kuba K, Mariash CN, Oppenheimer JH.
`Comparison of the effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine
`in the treatment of hypercholesterolemia. Am J Med 1984;77:475-481.
`Bantle JP, Nath KA, Sutherland DER, Najarian JS, Ferris TF. Effects of cyclosporine on
`the renin-angiotensin-aldosterone system and potassium clearance in renal transplant
`recipients. Arch Intern Med 1985;145:505-508. Summarized in 1986 Year Book of
`Medicine.
`Beyer HS, Bantle JP, Mariash CN, Steffes MW, Seljeskog EL, Oppenheimer JH. Use of
`the dexamethasone-adrenocorticotropin test to assess the requirement for continued
`glucocorticoid replacement therapy after pituitary surgery. J Clin Endocrinol Metab
`1985;60:1012-1018.
`
`10.
`
`12.
`
`13.
`
`14.
`
`
`
`6
`
`MPI EXHIBIT 1027 PAGE 6
`
`

`

`
`15.
`
`16.
`
`17.
`
`18.
`19.
`20.
`
`21.
`
`22.
`23.
`24.
`
`25.
`
`26.
`27.
`28.
`29.
`
`30.
`31.
`32.
`
`33.
`34.
`35.
`
`
`
`Bantle JP, Lee CKK, Levitt SH. Thyroxine administration during radiation therapy to the
`neck does not prevent subsequent thyroid dysfunction. Int J Radiat Oncol Biol Phys.
`1985;11:1999-2002.
`Hoogwerf BJ, Bantle JP, Gaenslen HE, Greenberg BZ, Senske BJ, Francis R, Goetz FC.
`Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or
`plasma glucagon in healthy subjects. Metabolism 1986;35:122-125.
`The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT):
`design and methodologic considerations for the feasibility phase. Diabetes 1986;35:530-
`545.
`Bantle JP, Laine DC, Thomas JW. Metabolic effects of dietary fructose and sucrose in
`type I and type II diabetic subjects. JAMA 1986;256:3241-3246.
`The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT):
`results of the feasibility study (phase II). Diabetes Care 1987;10:1-19.
`Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH.
`Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of
`hypothyroidism: Role of T3 in pituitary feedback in man. N Engl J Med 1987;316:764-
`770.
`Laine DC, Thomas JW, Levitt MD, Bantle JP. Comparison of the predictive capabilities
`of the diabetic Exchange Lists and the Glycemic Index of Foods. Diabetes Care 1987;
`10:387-394.
`Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine.
`Am J Med 1987;83:59-64.
`Bantle JP, Laine DC. Day-to-day variation in glycemic control in type I and type II
`diabetes mellitus. Diabetes Res 1988;8:147-149.
`Bantle JP, Paller MS, Boudreau RJ, Olivari MT, Ferris TF. Long-term effects of
`cyclosporine on renal function in organ transplant recipients. J Lab Clin Med
`1990;115:233-240.
`Bantle JP, Weber MS, Rao SMS, Chattopadhyay MK, Robertson RP. Rotation of the
`anatomic regions used for insulin injections and day-to-day variability of plasma glucose
`in type I diabetic subjects. JAMA 1990;263:1802-1806. Summarized in 1991 Year Book
`of Medicine.
`The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Update.
`Diabetes Care 1990;13:427-433.
`Swanson JE, Laine DC, Thomas W, Bantle JP. Metabolic effects of dietary fructose in
`healthy subjects. Am J Clin Nutr 1992;55:851-856.
`Bantle JP, Swanson JE, Thomas W, Laine DC. Metabolic effects of dietary fructose in
`diabetic subjects. Diabetes Care 1992;15:1468-1476.
`The DCCT Research Group. The effect of intensive treatment of diabetes on the
`development and progression of long-term complications in insulin-dependent diabetes
`mellitus. N Engl J Med 1993;329:977-986. Summarized in 1994 Year Book of Medicine.
`Bantle JP, Swanson JE, Thomas W, Laine DC. Metabolic effects of dietary sucrose in
`type II diabetic subjects. Diabetes Care 1993;16:1301-1305.
`Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin
`injections on glycemia in type I diabetic subjects. Diabetes Care 1993;16:1592-1597.
`Garg A, Bantle JP, Henry RR, Coulston AM, Griver K, Raatz SK, Brinkley L, Chen YD,
`Grundy SM, Huet BA, Reaven GM. Long-term effects of varying carbohydrate content
`of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 1994;271:1421-
`1428.
`Campbell JA, Schmidt BA, Bantle JP. Sucralfate and the absorption of L-thyroxine. Ann
`Intern Med 1994;121:152 (letter).
`The DCCT Research Group. Implementation of conventional and intensive treatment in
`the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361-375.
`The DCCT Research Group. The effect of intensive diabetes treatment on the progression
`of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and
`Complications Trial. Arch Ophthalmol 1995;113:36-51.
`7
`
`MPI EXHIBIT 1027 PAGE 7
`
`

`

`
`36.
`
`37.
`
`38.
`39.
`40.
`41.
`
`42.
`
`43.
`
`44.
`
`45.
`46.
`
`The DCCT Research Group. The effect of intensive diabetes therapy on the development
`and progression of neuropathy in the Diabetes Control and Complications Trial. Ann
`Intern Med 1995;122:561-568.
`The DCCT Research Group. The effect of intensive therapy on the development and
`progression of diabetic nephropathy in the Diabetes Control and Complications Trial.
`Kidney Int 1995;47:1703-1720.
`Bhatia S, Ramsay NKC, Bantle JP, Martens A, Robison LL. Thyroid abnormalities after
`therapy for Hodkins Disease in childhood. The Oncologist 1996;1:62-67.
`Bantle JP, Thomas W. Glucose monitoring using dermal interstitial fluid. J Lab Clin Med
`1997;130:436-441.
`Redmon B, Raatz SR, Bantle JP. Valvular heart disease associated with fenfluramine-
`phentermine. N Engl J Med 1997; 337:1773-1774 (letter).
`Georgopoulos A, Bantle JP, Swaim WR, Parker SJ. Differences in the metabolism of
`postprandial lipoproteins during a high monounsaturated fat versus a high carbohydrate
`diet in patients with IDDM. Arterioscler Thromb Vasc Biol 1998;18:773-782.
`The EDIC Research Group. Epidemiology of Diabetes Intervention and complications
`(EDIC): Design and implementation of a long-term follow-up of the Diabetes Control
`and Complications Trial cohort. Diabetes Care 1999;22:99-111.
`Redmon JB, Raatz SK, Kwong C, Swanson J, Thomas JW, Bantle JP. Pharmacologic
`induction of weight loss to treat type 2 diabetes mellitus. Diabetes Care 1999;22:896-
`903.
`The EDIC Research Group. The effect of intensive diabetes treatment on carotid artery
`wall thickness in the Epidemiology of Diabetes Interventions and Complications (EDIC).
`Diabetes 1999;48:383-390.
`The DCCT/EDIC Research Group. Retinopathy and nephropathy in patients with type 1
`diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389.
`Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP. Chronic
`treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am J
`Cardiol 2000;85:913-915.
`The DCCT Research Group. Effects of pregnancy on microvascular complications in the
`Diabetes Control and Complications Trial. Diabetes Care 2000;23:1084-1091.
`Bantle JP, Raatz SK, Georgopoulos A, Thomas W. Effects of dietary fructose on plasma
`lipids in healthy subjects. Am J Clin Nutr 2000;72:1128-1134.
`Georgopoulos A, Bantle JP, Noutsou M, Hoover HA. A high carbohydrate versus a high
`monounsaturated fatty acid diet lowers the atherogenic potential of big VLDL particles in
`patients with type 1 diabetes. J Nutr 2000;130:2503-2507.
`The DCCT/EDIC Research Group. Intensive diabetes therapy and carotid intima-media
`thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-2303.
`The DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1
`diabetes mellitus on development and progression of diabetic nephropathy. JAMA 2003;
`290:2159-2167.
`Redmon JB, Raatz SA, Reck KP, Swanson JE, Kwong CA, Fan Q, Thomas W, Bantle JP.
`A combination of weight loss therapies for subjects with type 2 diabetes mellitus.
`Diabetes Care 2003;26:2505-2511.
`Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design
`and methods for a clinical trial of weight loss for the prevention of cardiovascular
`disease in type 2 diabetes. Control Clin Trials 2003;24;610-628.
`54. Mucha GT, Merkel S, Thomas W, Bantle JP. Fasting and insulin glargine in persons with
`type 1 diabetes mellitus. Diabetes Care 2004;27:1209-1210.
`Redmon JB, Reck KP, Raatz SK, Swanson JE, Kwong CA, Hong J, Thomas W, Bantle
`55.
`JP. Two year outcome of a combination of weight loss therapies for type 2 diabetes.
`Diabetes Care 2005;28:1311-1315.
`Raatz, SK, Torkelson CJ, Redmon JB, Reck KP, Kwong CA, Swanson JE, Chengcheng
`L, Thomas W, Bantle JP. Reduced glycemic index and glycemic load diets do not
`
`47.
`48.
`49.
`
`50.
`51.
`
`52.
`
`53.
`
`56.
`
`
`
`8
`
`MPI EXHIBIT 1027 PAGE 8
`
`

`

`
`
`57.
`
`58.
`59.
`
`66.
`
`increase the effects of energy restriction on weight loss and insulin sensitivity in obese
`men and women. J Nutr 2005;135:2387-2391.
`Shah M, Adams-Huet B, Bantle JP, Henry RR, Griver KA, Raatz SK, Brinkley LJ,
`Reaven GM, Garg A. Effect of a high-carbohydrate versus a high-cis-monounsaturated
`fat diet on blood pressure in patients with type 2 diabetes. Diabetes Care 2005;28:2607-
`2612.
`The DCCT/EDIC Research Group. Intensive diabetes treatment and cardiovascular
`disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
`Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ
`for the BARI 2D Trial Investigators. Hypotheses, design and methods for the bypass
`angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Am J Cardiol
`2006;97[suppl]:9G-19G.
`60.
`Look AHEAD Research Group. The Look AHEAD study: a description of the lifestyle
`intervention and the evidence supporting it. Obesity 2006;14:737-752.
`61.
`Bantle JP, Ikramuddin S, Kellogg TA, Buchwald H. Hyperinsulinemic hypoglycemia
`developing late after gastric bypass. Obesity Surgery 2007;17:592-594.
`62.
`Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk
`factors in individuals with type 2 diabetes. Diabetes Care 2007;30:1374-1383.
`63.
`Bantle AE, Thomas W, Bantle JP. Metabolic effects of alcohol in the form of wine in
`persons with type 2 diabetes mellitus. Metabolism 2008;57:241-245.
`64.
`Bertoni AG, Clark JM, Feeney P, Yanovski SZ, Bantle J, Montgomery B, Safford MM,
` Herman WH, Haffner S and the Look AHEAD Research Group. Suboptimal control of
` glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the
` Look AHEAD Study. J Diabetes Complications 2008;22:1-9.
`BARI 2D Study Group. Baseline characteristics of patients with diabetes and coronary
`65.
`artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2
`Diabetes (BARI 2D) trial. Am Heart J 2008;156:528-536.
`Kellogg TA, Bantle JP, Leslie DB, Redmon JB, Slusarek B, Swan T, Buchwald H,
`Ikramuddin S. Postgastric bypass hyperinsulinemic hypoglycemia syndrome:
`characterization and response to a modified diet. Surg Obes Relat Dis 2008;4:492-499.
`BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary
`artery disease. N Engl J Med 2009;360:2503-2515.
`The DCCT/EDIC Research Group. Modern-day clinical course of type 1 diabetes
`mellitus after 30 years’ duration. Arch Intern Med 2009;169:1307-1316.
`Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight
`and cardiovascular risk factors in individuals with type 2 diabetes. Arch Intern Med
`2010;170:1566-1575.
`The DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration
`rate in type 1 diabetes. N Engl J Med 2011;365:2366-2376.
`Abdelmalek MF, Lazo M, Horska A, Bonekamp S, Lipkin EW, Balasubramanyam A,
`Bantle JP, Johnson RJ, Diehl AM, Clark JM and the Fatty Liver Subgroup of the Look
`AHEAD Research Group. Higher dietary fructose is associated with impaired hepatic
`ATP homeostasis in obese individuals with type 2 diabetes. Hepatology 2012;56:952-
`960.
`Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, Pownall HJ,
`Johnson KC, Safford M, Kitabchi AE, Pi-Sunyer FX, Wing RR, Bertoni AG and the
`Look AHEAD Research Group. Association of an intensive lifestyle intervention with
`remission of type 2 diabetes. JAMA 2012;308:2489-2496.
`Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ,
`Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG,
`Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive
`medical management for control of type 2 diabetes, hypertension and hyperlipidemia:
`The diabetes surgery study randomized clinical trial. JAMA 2013;309:2240-2249.
`The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle
`intervention in type 2 diabetes. N Engl J Med 2013;369:145-154.
`9
`
`67.
`68.
`69.
`
`70.
`71.
`
`72.
`
`73.
`
`74.
`
`
`
`MPI EXHIBIT 1027 PAGE 9
`
`

`

`
`75.
`
`76.
`
`77.
`78.
`
`79.
`
`80.
`
`81.
`
`82.
`83.
`84.
`
`Khowaja A, Johnson-Rabbett B, Bantle J, Moheet A. Hypoglycemia mediated by
`paraneoplastic production of insulin like growth factor-2 from a malignant renal solitary
`fibrous tumor. BMC Endocrine Disorders 2014;14:49.
`The Look AHEAD Research Group. Effect of long-term behavioural weight loss
`intervention on nephropathy in overweight or obese adults with type 2 diabetes: a
`secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes
`Endocrinol 2014;2:801-809.
`DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type
`1 diabetes and long-term mortality. JAMA 2015;313:45-53.
`Ikramuddin S, Billington CJ, Lee WJ, Bantle JP, Thomas AJ, Connett JE, Leslie DB,
`Inabnet WB, Jeffery RW, Keong C, Chuang LM, Sarr MG, Jensen MD, Vella A, Ahmed
`L, Belani K, Schone JL, Reynolds AE, Bainbridge HA, Wang Q, Korner J. Benefits and
`risks of roux-en-Y gastric bypass for diabetes: two year outcomes of the diabetes surgery
`study. Lancet Diabetes Endocrinol 2015; 3:413-422.
`Bantle AE, Wang Q, Bantle JP. Post-gastric bypass hyperinsulinemic hypoglycemia:
`fructose is a carbohydrate which can be safely consumed. J Clin Endocrinol Metab
`2015;100:3097-3102.
`Nguyen KT, Billington CJ, Vella A, Wang Qi, Ahmed L, Bantle JP, Bessler M, Connett,
`JE, Inabnet WB, Thomas A, Ikramuddin S, Korner J. Preserved insulin secretory capacity
`and weight loss are the predominant predictors of glycemic control in patients with type 2
`diabetes randomized to roux-en-Y gastric bypass. Diabetes 2015;64:3104-3110.
`Ikramuddin S, Korner J, Lee W-J, Bantle JP, Thomas AJ, Connett JE, Leslie DB, Inabnet
`WB, Wang Q, Jeffery RW, Chong K, Chuang L-M, Jensen MD, Vella A, Ahmed L,
`Belani K, Olofson AE, Bainbridge HA, Billington CJ. Durability of addition of Roux-en-
`Y gastric bypass to lifestyle intervention and medical management in achieving primary
`treatment goals for uncontrolled diabetes in mild to moderate obesity: a randomized
`clinical trial. Diabetes Care 2016;39:1510-1518.
`DCCT/EDIC Research Group. Risk factors for cardiovascular disease in type 1 diabetes.
`Diabetes 2016;65:1370-1379.
`Buchwald H, Oien DM, Schieber DJ, Bantle JP, Connett JE. Partial ileal bypass affords
`protection from onset of type 2 diabetes. Surg Obes Relat Dis 2017;13:45-52.
`Chong K, Ikramuddin S, Lee W, Billington CJ, Bantle JP, Wang Q, Thomas AJ, Connett
`JE, Leslie DB, Inabnet WB, Jeffery RW, Sarr MG, Jensen MD, Vella A, Ahmed L,
`Belani K, Schone JL, Olofson AE, Bainbridge HA, Laqua PS, Korner J, Chuang L.
`National differences in remission of type 2 diabetes mellitus after roux-en-Y gastric
`bypass surgery - subgroup analysis of 2-year results of the diabetes surgery study
`comparing Taiwanese with Americans with mild obesity (BMI 30-35 kg/m2). Obes Surg
`2017;27:1189-1195.
`Purnell JQ, Braffett BH, Zinman B, Hokanson JE, Gubitoski-Klug RA, Sivitz W, Bantle
`JP, Ziegler G, Cleary PA, Brunzell JD and the DCCT/EDIC Research Group. Impact of
`excessive weight gain on cardiovascular outcomes in type 1 diabetes: Results from the
`Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and
`Complication Study (DCCT/EDIC). Diabetes Care 2017;40:1756-1762.
`Ikramuddin S, Korner J, Lee WJ, Thomas AJ, Connett JE, Bantle JP, Leslie DB, Wang
`Q, Inabnet WB, Jeffery RW, Chong K, Chuang LM, Jensen MD, Vella A, Ahmed L,
`Belani K, Billington CW. Lifestyle intervention and medical management with vs
`without roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and
`systolic blood pressure at 5 years in the diabetes surgery study. JAMA 2018;319:266-278.
`Genuth SM, Vlachos H, Brooks MM, Bantle JP, Chaitman BR, Green J, Kelsey SF, King
`SB, McBane R, Sako EY, Schneider DJ, Steffes M, Frye RL and the BARI 2D Study
`Group. Bypass Angioplasty Revascularization Investigation 2 Diabetes: A reanalysis
`focusing on cardiovascular events. Mayo Clin Proc 2019;94:2249-2262.
`88. Wadden TA, Chao AM, Bahnson JL, Bantle JP, Blackburn GL, Clark JM, Gaussoin S,
`Jakicic JM, Johnson KC, Miller GD, Uniick JL, Yanovski SL. End-of-trial health
`
`85.
`
`86.
`
`87.
`
`
`
`10
`
`MPI EXHIBIT 1027 PAGE 10
`
`

`

`
`
`89.
`
`90.
`
`91.
`
`
`
`
`
`1.
`2.
`
`outcomes in Look AHEAD participants who elected to have bariatric surgery. Obesity
`2019;27:581-590.
`Yeh H-C, Bantle JP, Cassidy-Begay M, Blackburn G, Bray GA, Byers T, Clark JM,